Research output: Contribution to journal › Article › peer-review
Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Consortium, Thanos P Mourikis, Lorena Benedetti, Elizabeth Foxall, Damjan Temelkovski, Joel Nulsen, Juliane Perner, Matteo Cereda, Jesper Lagergren, Michael Howell, Christopher Yau, Rebecca C Fitzgerald, Paola Scaffidi, Francesca D Ciccarelli
Original language | English |
---|---|
Article number | 3101 |
Number of pages | 17 |
Journal | Nature Communications |
Volume | 10 |
Issue number | 1 |
Early online date | 15 Jul 2019 |
DOIs | |
Accepted/In press | 4 Jun 2019 |
E-pub ahead of print | 15 Jul 2019 |
Published | 1 Dec 2019 |
Additional links |
Patient-specific cancer genes_BENEDETTI_Accepted4May2019_GOLD AAM
Ciccarelli_accept_rev4.pdf, 418 KB, application/pdf
Uploaded date:27 Jun 2019
Version:Accepted author manuscript
Licence:CC BY
Patient_specific_cancer_genes_contribute_to_recurrently_perturbed_pathways_CICCARELLI_Publishedonline15July2019_GOLD_CORRECTED_PROOF_CC_BY_.pdf, 4.16 MB, application/pdf
Uploaded date:04 Jan 2021
Version:Proof
Licence:CC BY
Patient-specific cancer genes_MOURIKIS_Accepted4June2019Publishedonline15July2019_GOLD VoR (CC BY)
Patient_specific_cancer_genes_MOURIKIS_Accepted4June2019Publishedonline15July2019_GOLD_VoR_CC_BY_.pdf, 4.16 MB, application/pdf
Uploaded date:23 Jul 2019
Version:Final published version
Licence:CC BY
The identification of cancer-promoting genetic alterations is challenging particularly in highly unstable and heterogeneous cancers, such as esophageal adenocarcinoma (EAC). Here we describe a machine learning algorithm to identify cancer genes in individual patients considering all types of damaging alterations simultaneously. Analysing 261 EACs from the OCCAMS Consortium, we discover helper genes that, alongside well-known drivers, promote cancer. We confirm the robustness of our approach in 107 additional EACs. Unlike recurrent alterations of known drivers, these cancer helper genes are rare or patient-specific. However, they converge towards perturbations of well-known cancer processes. Recurrence of the same process perturbations, rather than individual genes, divides EACs into six clusters differing in their molecular and clinical features. Experimentally mimicking the alterations of predicted helper genes in cancer and pre-cancer cells validates their contribution to disease progression, while reverting their alterations reveals EAC acquired dependencies that can be exploited in therapy.
King's College London - Homepage
© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454